Influx Healthtech FY26: Growth Accelerates as Capacity Expansion Becomes the Main Story

Influx Healthtech Limited closed FY26 with a sharp step-up in scale and profitability, supported by strong growth in its core nutraceutical CDMO business. Revenue from operations rose to INR 146.8 crore, up 40% year-on-year. EBITDA increased to INR 29.9 crore, up 45%, and profit after tax came in at INR 20.5 crore, up 54%. Margins improved as well, with EBITDA margin at 20.3% and PAT margin at 14.0%.

The headline performance was paired with a heavier emphasis on expansion. Management commentary across the investor presentation and the earnings call repeatedly returned to one central theme: adding capacity ahead of demand and building a larger, more scalable nutraceutical platform. The company ended FY26 with four manufacturing facilities in Palghar, Maharashtra (one stated as rented in the presentation), and talked through multiple production lines that have been commissioned or ordered.

FY26 performance, segment mix, and what drove growth

Influx Healthtech describes itself as a formulation-driven, brand-focused healthcare CDMO, operating across nutraceuticals, cosmetics, ayurveda, veterinary and homecare. In practice, FY26 remained dominated by nutraceutical manufacturing.

Nutraceuticals delivered INR 131.9 crore of revenue in FY26, a 40.3% year-on-year increase. Cosmetics contributed INR 7.4 crore (15.8% YoY). Ayurvedic products rose to INR 6.1 crore (88.9% YoY), off a smaller base. The others bucket, which includes veterinary and homecare, contributed INR 1.4 crore (18.7% YoY). The revenue mix stayed broadly steady, with nutraceuticals at 90% in both FY25 and FY26.

Management highlighted that the company’s product breadth is a differentiator. The presentation cites 3,400 plus products and 700 plus customers. The call added color that revenue in nutraceuticals is largely driven by tablets, capsules, and powders, with gummies also meaningful.

One operational positive in FY26 was improvement in receivables days, which declined to 84 days from 113 days in FY25, as per the presentation. However, the broader working capital profile moved in the opposite direction because payable days fell sharply and the cash conversion cycle expanded.

Financial summary (FY26 vs FY25)

The income statement shows a cost structure that grew with scale. For FY26, cost of materials consumed was INR 86.7 crore, employee benefits expense was INR 11.8 crore, and other expenses were INR 18.5 crore. Management specifically attributed higher employee costs to workforce addition for upcoming RTD and nutraceutical units and annual salary increments.

Capacity build-out and IPO fund reallocation

The most material forward-looking development is the expansion of the nutraceutical CDMO facility. In the conference call, management described a new facility of about 75,000 square feet (ground plus four floors), expected to be ready around July or August 2026, followed by licensing. They stated that, upon commissioning, it is anticipated to increase overall installed capacity by about 2.5 times.

A key disclosure was the variation in utilization of IPO proceeds. The board approved reallocation of about INR 10 crore primarily from surplus amounts across the veterinary facility, homecare, and cosmetic divisions toward the higher construction cost of the nutraceutical CDMO facility. In the presentation table, total reallocated out is shown as INR 1,009.31 lakh. Management explained the scale-up as an expansion from about 35,000 to 75,000 square feet and linked the increase to GMP-compliant design and upgrades such as HVAC and improved material flow.

The company also discussed capex already commissioned through internal accruals in H1FY26, including a multi-line production setup and specific expansions in tablet and capsule manufacturing. It reported total capex of INR 25 crore in FY26.

This expansion push is not limited to nutraceutical tablets and powders. The machinery ordered list in the presentation includes an automated beverage manufacturing line, a retort manufacturing system, a sachet card machine, a high-capacity pet food production line, and a four-track ALU blister packaging machine.

Beverages, pet care, exports, and the next set of growth levers

Influx has taken a structural step into beverages by incorporating a wholly owned subsidiary, Olahey Wellness Private Limited, with an INR 1 lakh cash investment. Management described plans to build a canning facility and a carbonated beverage line, with a Tetra pack line booked and planned installed capacity of about 10,000 bottles per hour. The company positioned the beverage push as focused on functional and ready-to-drink formats, including retort-based liquid nutrition products.

In pet care, management stated current output is around 16 to 18 tons per month, with near-term capacity expected to reach 25 tons per month within two to three months. A high-capacity extrusion line has been ordered to increase throughput from 100 to 150 kg per hour to 1,000 kg per hour, which the presentation describes as about an 8 times enhancement. Management emphasized utilization will ramp over time, and that scale can also help margins.

Exports also emerged as a recurring theme. The presentation states export countries increased to 36 in FY26 from 11 in FY25. In the call, management said it has received regulatory approvals for Tanzania and Nigeria, with Kenya under consideration. The company also mentioned establishing a new office in the UAE focused on higher-margin opportunities and stated that export growth has been running at 10% to 15% annually.

What management guided for FY27

Management guidance was direct on growth and margin direction. The presentation states FY27 growth guidance of 25% to 30% with similar margins. On the call, management reiterated the same growth band and also indicated an EBITDA margin range of around 20% to 22% and maintaining PAT margin of around 14%.

The facility commissioning timeline was also discussed with some specificity. Management said the new facility should be ready by July or August 2026 and that operations should begin in the second half after licensing. It also indicated the new facility could contribute around INR 40 to 50 crore of revenue in FY27 if execution goes well. Separately, management linked the capacity build to a longer-term revenue ambition of around INR 450 to 500 crore by FY29.

Key takeaways for investors

Influx Healthtech’s FY26 results show strong growth and margin expansion, with nutraceuticals continuing to dominate the revenue base. The company is deploying IPO funds and internal accruals toward a much larger nutraceutical facility and adjacent capabilities in beverages and pet care.

The two areas that stand out as investor watchpoints are revenue concentration and cash conversion. The presentation shows top 10 clients contributing 49% of revenue in FY26, and the cash conversion cycle moved to 64 days, with cash flow from operations at INR 3.9 crore despite PAT of INR 20.5 crore.

FY27 will likely be judged on execution against timelines: commissioning and licensing of the expanded facility, ramp-up of newly ordered machinery, and whether growth can be sustained within the guided 25% to 30% band while keeping margins stable.